Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 4:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions: Airiver ESSpand DCB, ESS; Combination Product · Procedure
Lead sponsor: Airiver Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 16
States / cities: Birmingham, Alabama • Huntsville, Alabama • San Diego, California + 11 more

Conditions: Ocular Hypertension, Open-angle Glaucoma
Interventions: Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Congenital Heart Diseases, Cardiac Diseases
Interventions: Not listed
Lead sponsor: Matthias Stuber; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Chronic Hepatitis C Infection
Interventions: Fuzheng Huayu, Placebo; Drug
Lead sponsor: Tarek Hassanein; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Coronado, California • Palo Alto, California • Pasadena, California + 5 more

Conditions: Lateral Canthal Lines
Interventions: RT001, Placebo; Drug · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 30 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 9
States / cities: Birmingham, Alabama • San Francisco, California • Coral Gables, Florida + 5 more

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
Interventions: EP2101; Biological
Lead sponsor: Epimmune; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Los Angeles, California • Orlando, Florida • Albany, New York + 5 more

Conditions: Alzheimer's Disease
Interventions: ABT-126; Drug
Lead sponsor: Abbott; Industry
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Herpes Zoster, Postherpetic Neuralgia
Interventions: ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir; Drug
Lead sponsor: aRigen Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Beverly Hills, California • Encino, California • Vista, California + 5 more

Conditions: PAH
Interventions: CXA-10; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more

Conditions: Crohn's Disease
Interventions: Certolizumab Pegol (CDP870); Biological
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more

Conditions: Chronic Kidney Disease, Chronic Kidney Disease, Stage 3 (Moderate), Chronic Kidney Disease, Stage 4 (Severe), Diabetes
Interventions: DM199; Drug
Lead sponsor: DiaMedica Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: Hialeah, Florida • Orlando, Florida • Saint Paul, Minnesota

Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions: Ixo-vec, Aflibercept; Genetic · Drug
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 79
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 30
States / cities: Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 24 more

Conditions: Achromatopsia
Interventions: AAV - CNGB3; Biological
Lead sponsor: MeiraGTx UK II Ltd; Industry
Eligibility: 3 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: T1DM - Type 1 Diabetes Mellitus
Interventions: 13 CGM (continuous glucose monitor); Device
Lead sponsor: Sinocare; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Low Back Pain
Interventions: Interspinous process and dynamic stabilization (Wallis System), Total Disc Replacement; Device
Lead sponsor: Zimmer Spine; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 11
States / cities: Beverly Hills, California • Encinitas, California • Boulder, Colorado + 8 more

Conditions: Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions: SUN-627, Placebo; Drug · Other
Lead sponsor: Sundance Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Stony Brook, New York + 4 more

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more

Conditions: Healthy
Interventions: cefdinir (Omnicef), azithromycin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 4 Years to 8 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2003
U.S. locations: 3
States / cities: Scottsdale, Arizona • St. Petersburg, Florida • Miamiville, Ohio

Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS), MS, MS (Multiple Sclerosis), Neuro-Degenerative Disease, Neuro-Degenerative Diseases, Autoimmune
Interventions: C-CAR168; Drug
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Gilbert, Arizona • La Jolla, California

Conditions: Non Small Cell Lung Cancer
Interventions: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), Technetium 99m ethylenedicysteine-deoxyglucose, 18 F fluorodeoxyglucose; Radiation
Lead sponsor: Cell>Point LLC; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota • The Bronx, New York

Conditions: Alzheimer's Disease
Interventions: LY2062430, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 3 more

Conditions: Lymphatic Disease, HIV Infections
Interventions: Inosine pranobex; Drug
Lead sponsor: Newport Pharmaceuticals International; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Laguna Hills, California

Search by objective public record fields.

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function

Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

A Safety and Tolerability Study of ABT-126 in Elderly

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

Study to Assess PK, Safety and Tolerability in Patients With DM and CKD

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

Gene Therapy for Achromatopsia (CNGB3)

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

The True Vie I3 Continuous Glucose Monitoring System in Pediatric Patients With Type 1 Diabetes Mellitus

Wallis Stabilization System for Low Back Pain

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

A Pediatric Taste Test Study of Omnicef Versus Zithromax Antibiotic Suspension Medications

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy

Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

A Study of Isoprinosine in Patients With Lymph Node Disease